• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

We know accurately only when we know little.

作者信息

MacLeod Stuart, Mitton Craig

出版信息

Pharmacoeconomics. 2010;28(2):105-7. doi: 10.2165/11531510-000000000-00000.

DOI:10.2165/11531510-000000000-00000
PMID:20085387
Abstract
摘要

相似文献

1
We know accurately only when we know little.仅当我们所知甚少时，我们才确切地知道。
Pharmacoeconomics. 2010;28(2):105-7. doi: 10.2165/11531510-000000000-00000.
2
Linking insurance coverage for innovative invasive procedures with participation in clinical research.将创新性侵入性手术的保险覆盖范围与参与临床研究联系起来。
JAMA. 2011 Nov 9;306(18):2024-5. doi: 10.1001/jama.2011.1631.
3
Real world data.真实世界数据。
Value Health. 2007 Sep-Oct;10(5):322-3. doi: 10.1111/j.1524-4733.2007.00277.x.
4
Getting research findings into practice. When to act on the evidence.将研究成果应用于实践。何时依据证据采取行动。
BMJ. 1998 Jul 11;317(7151):139-42. doi: 10.1136/bmj.317.7151.139.
5
Physician stewardship of health care in an era of finite resources.资源有限时代下医生对医疗保健的管理
JAMA. 2011 Jul 27;306(4):430-1. doi: 10.1001/jama.2011.999.
6
Lung volume reduction surgery: tempest in a teapot.
J Thorac Cardiovasc Surg. 2003 Mar;125(3):457-9. doi: 10.1067/mtc.2003.434.
7
An outcomes-based approach to decisions about drug coverage policies in British Columbia.不列颠哥伦比亚省基于结果的药物覆盖政策决策方法。
Psychiatr Serv. 2004 Nov;55(11):1230-2. doi: 10.1176/appi.ps.55.11.1230.
8
Making sense of the evidence using comparative effectiveness to guide clinical decision making, policy and coverage.利用比较效果研究证据来指导临床决策、政策制定及医保覆盖范围。
Acad Radiol. 2011 Sep;18(9):1065-6. doi: 10.1016/j.acra.2011.06.002.
9
What explains the diffusion of treatments for mental illness?如何解释精神疾病治疗方法的传播？
Am J Psychiatry. 2008 Nov;165(11):1385-92. doi: 10.1176/appi.ajp.2008.08030334.
10
Implementing evidence-based medicine through medicare coverage decisions.通过医疗保险覆盖范围决策实施循证医学。
Health Aff (Millwood). 2007 Nov-Dec;26(6):1634-42. doi: 10.1377/hlthaff.26.6.1634.

引用本文的文献

1
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.实施基于结果的罕见病治疗管理准入协议：诺西那生钠和Tisagenlecleucel。
Pharmacoeconomics. 2021 Sep;39(9):1021-1044. doi: 10.1007/s40273-021-01050-5. Epub 2021 Jul 7.
2
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.政治及其与循证决策覆盖的交织：专家访谈的定性分析。
BMC Health Serv Res. 2013 Mar 9;13:88. doi: 10.1186/1472-6963-13-88.
3
Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.

本文引用的文献

1
Access with evidence development in the UK: past experience, current initiatives and future potential.在英国，通过循证方法获取医疗资源：过去的经验、当前的举措和未来的潜力。
Pharmacoeconomics. 2010;28(2):163-70. doi: 10.2165/11531410-000000000-00000.
2
Access with evidence development: the US experience.循证准入：美国经验。
Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000.
3
Access with evidence development schemes: a framework for description and evaluation.有证据开发计划的获取：一种描述和评价的框架。
英国国家卫生与临床优化研究所的单一技术评估：国际决策的证据与分析来源
Pharmacoeconomics. 2010;28(5):347-9. doi: 10.2165/11535680-000000000-00000.
Pharmacoeconomics. 2010;28(2):143-52. doi: 10.2165/11530850-000000000-00000.
4
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.为无法资助的项目提供资金：在将新技术和创新技术引入医疗保健系统的决策中管理不确定性的机制。
Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000.
5
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.采用循证发展方法的获取设计原则：班夫峰会共识声明
Pharmacoeconomics. 2010;28(2):109-11. doi: 10.2165/11530860-000000000-00000.
6
Comparative effectiveness research and evidence-based health policy: experience from four countries.比较效果研究与循证卫生政策：来自四个国家的经验
Milbank Q. 2009 Jun;87(2):339-67. doi: 10.1111/j.1468-0009.2009.00560.x.
7
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.证据与价值：罕见病药物公共报销的要求——肿瘤学案例研究
Can J Clin Pharmacol. 2009 Summer;16(2):e273-81; discussion e282-4. Epub 2009 May 13.
8
The Alberta Hip and Knee Replacement Project: a model for health technology assessment based on comparative effectiveness of clinical pathways.艾伯塔省髋关节和膝关节置换项目：基于临床路径比较效果的卫生技术评估模型。
Int J Technol Assess Health Care. 2009 Apr;25(2):113-23. doi: 10.1017/S0266462309090163.
9
Commentary: whose views count in evidence synthesis? And when do they count?评论：在证据综合中谁的观点重要？以及何时重要？
Healthc Policy. 2006 Jan;1(2):55-7.
10
Accountability for reasonableness: an update.合理性问责制：最新情况
BMJ. 2008 Oct 9;337:a1850. doi: 10.1136/bmj.a1850.